000 03975nlm1a2200553 4500
001 665597
005 20231030042008.0
035 _a(RuTPU)RU\TPU\network\36797
035 _aRU\TPU\network\34978
090 _a665597
100 _a20211022a2021 k y0engy50 ba
101 0 _aeng
135 _adrcn ---uucaa
181 0 _ai
182 0 _ab
200 1 _aAntitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio
_fO. U. Cruz-Ramirez, L. M. Valenzuela-Salas, A. Blanco-Salazar [et al.]
203 _aText
_celectronic
300 _aTitle screen
320 _a[References: 68 tit.]
330 _aSilver nanoparticles (AgNPs) not only have shown remarkable results as antimicrobial and antiviral agents but also as antitumor agents. This work reports the complete characterization of five polyvinylpyrrolidone-coated AgNP (PVP-AgNP) formulations, their cytotoxic activity against human colon tumor cells (HCT-15), their cytotoxic effect on primary mouse cultures, and their lethal dose on BALB/c mice. The evaluated AgNP formulations have a composition within the ranges Ag: 1.14-1.32% w/w, PVP: 19.6-24.5% and H2O: 74.2-79.2% with predominant spherical shape within an average size range of 16-30 nm according to transmission electron microscopy (TEM). All formulations assessed increase mitochondrial ROS concentration and induce apoptosis as the leading death pathway on HCT-15 cells. Except for AgNP1, the growth inhibition potency of AgNP formulations of human colon tumor cancer cells (HCT-15) is 34.5 times higher than carboplatin, one of the first-line chemotherapy agents. Nevertheless, 5-10% of necrotic events, even at the lower concentration evaluated, were observed. The cytotoxic selectivity was confirmed by evaluating the cytotoxic effect on aorta, spleen, heart, liver, and kidney primary cultures from BALB/c mice. Despite the cytotoxic effects observed in vitro, the lethal dose and histopathological analysis showed the low toxicity of these formulations (all of them on Category 4 of the Globally Harmonized System of Classification and Labelling of Chemicals) and minor damage observed on analyzed organs. The results provide an additional example of the rational design of safety nanomaterials with antitumor potency and urge further experiments to complete the preclinical studies for these AgNP formulations.
461 _tPharmaceutics
463 _tVol. 13, iss. 7
_v[1000, 16 p.]
_d2021
610 1 _aэлектронный ресурс
610 1 _aтруды учёных ТПУ
610 1 _aAgNPs
610 1 _aantitumor activity
610 1 _acolon cancer
610 1 _aHCT-15
610 1 _acytotoxic selectivity
610 1 _a[metal]/[coating agent] ratio
610 1 _atherapeutic index
610 1 _aGSH classification
610 1 _aпротивоопухолевая терапия
610 1 _aрак
610 1 _aцитотоксические свойства
701 1 _aCruz-Ramirez
_bO. U.
701 1 _aValenzuela-Salas
_bL. M.
_gLucia
701 1 _aBlanco-Salazar
_bA.
_gAlberto
701 1 _aRodriguez-Arenas
_bJ. A.
701 1 _aMier-Maldonado
_bP. A.
_gParis
701 1 _aGarcia-Maldonado
_bP. A.
701 1 _aGarcia-Ramos
_bJ. C.
_gJuan Carlos
701 1 _aBogdanchikova
_bN.
_gNina
701 1 _aPestryakov
_bA. N.
_cChemist
_cProfessor of Tomsk Polytechnic University, Doctor of Chemical Science
_f1963-
_gAleksey Nikolaevich
_2stltpush
_3(RuTPU)RU\TPU\pers\30471
701 1 _aToledano-Magana
_bYa.
_gYanis
712 0 2 _aНациональный исследовательский Томский политехнический университет
_bИсследовательская школа химических и биомедицинских технологий
_c(2017- )
_h8120
_2stltpush
_3(RuTPU)RU\TPU\col\23537
801 2 _aRU
_b63413507
_c20211022
_gRCR
856 4 _uhttps://doi.org/10.3390/pharmaceutics13071000
942 _cCF